The rise of Sildenafil initially sparked a period of growth for the drug industry, however recent shifts present a murky scenario for investors. Lower-cost versions are reducing revenue, and persistent litigation add https://louisetisw656583.acidblog.net/72434436/the-blue-pill-and-pharma-a-risky-bet